Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

Female-Owned Florida based Global Biotech Pharmaceutical Marketing Company, PharmEnvee, partners with BYD to Supply N95 Masks


Pharm Envee’s BYD KN95 face masks are CE certified, genuine and made in accordance with industry standards. The 5-ply foldable mask has up to 95% filtration efficiency of non-oily suspended particles of 0.3 micron levels. Ideal for daily use, helping prevent the spread of germs and protect yourself from airborne particles, viruses such as the coronavirus, pollen and other allergens.

Pharm Envee is also socially and environmentally conscious. The company has donated $50,000 worth of Personal Protective Equipment (PPE) to help Americans. The contributions includes supporting incarcerated women and staff at the Homestead Correctional Facility (Miami), senior citizens in Grand Prairie, Texas, children in Gary, Indiana , and being the PPE sponsor to protestors in Atlanta Georgia through the Take2Foundation and Martin Luther King Center.

Pharm Envee who is a strategic partner to international laboratories, manufacturers, pharmaceutical and trading companies worldwide has in total donated 1.2 Million PPE across the country as part of its support to Governments.

Matt Bowman, Managing Partner, Pharm Envee, a former Navy jet pilot, while donating the PPE to protesters during the just concluded Juneteenth Festival at Martin Luther King, Jr. National Historical Park, Atlanta stated;

“We are all in this together and have to help in as many different ways as possible and donating materials was a great first start to keep all Atlanta citizens safe,”

“As a strategic partner of international laboratories, manufacturers, pharmaceuticals, and trading companies. We are committed and would ensure that in all our work, BIPOC voices are represented, amplified, and heard by our clients and partners. We are developing and enforcing guidelines for vendors and experts that help shape our perspective” Matt Bowman said in the statement

Pharm Envee is still working to provide PPE to other parts of the country. As the need for PPE sourcing settles down, Ms. Sonia Kumar, President & CEO Pharm Envee plans to focus on helping global markets with supplies of biotechnological products and devices reach their high demands.

We are in the business of helping people for the long haul, there is no more important task in the world.

Share article on social media or email:

Respected NYC Cardiologist, Dr. Steven Reisman, Explains the Relationship Between the COVID-19 Pandemic and Heart Disease


Press - New York Cardiac Diagnostic Center

Press – New York Cardiac Diagnostic Center

Dr. Steven Reisman, MD, a nationally recognized cardiologist in NYC is the director of New York Cardiac Diagnostic Center. Dr. Reisman has authored numerous publications and presented original research at the American College of Cardiology & the American Heart Association.

Dr Reisman was recently interviewed on ‘ Inside Edition’ about Covid-19 and ‘Broken Heart Syndrome’. This condition also known as ‘Takotsubo cardiomyopathy’ was described several years ago in those with symptoms such as chest pain and shortness of breath mimicking a heart attack. This condition was found to occur in people experiencing acute emotional stress such as death of a loved one. It is different from a heart attack and usually only causes a transient disruption in the pumping function of the heart and can be diagnosed by office procedures such as an electrocardiogram (EKG) and an ultrasound of the heart or echocardiogram. Recently a study was reported showing an increase in the occurrence of this stress cardiomyopathy during the Covid-19 pandemic compared to previous years suggesting an increase in pandemic-related stress even in those not infected with Covid. It is possible that stress may be related to the psychological effects along with economic and social stress we are experiencing. Factors contributing to this may include fear of contracting the virus along with quarantine, physical distancing, and lack of social interactions.

A second pathway how Covid-19 causes heart disease is the direct effect on those who are infected with the virus. A recent study evaluated the findings on echocardiography in over 1200 Covid patients from 69 countries. In the entire group of patients , over one half or 55% had an abnormal echocardiogram suggesting abnormal heart function or structural abnormalities in the heart. Even in those with mild Covid disease 46% had an abnormal ultrasound scan of the heart. These results suggest that most of the abnormalities were not heart attacks but ‘non-specific’ patterns of heart muscle dysfunction easily detected on non-invasive echocardiography that can be performed in a doctor’s office.

About Dr Steven Reisman

Steven Reisman, MD is the founder and Director of the New York Cardiac Diagnostic Center serving patients from around the world since 1987. Dr Reisman has authored numerous publications and presented original research at the American College of Cardiology and the American Heart Association focusing on diagnostic techniques to detect heart disease. NYC heart doctor, Dr Reisman , has been featured on FOX, CNN, CBS, Forbes, the Washington Post , the Huffington Post and many other publications and tv shows commenting on the latest techniques in diagnostic cardiology. The New York Cardiac Diagnostic Center emphasizes individual attention and ease of setting up appointments and consultations.

Contact:

Upper East Side Cardiology

New York Cardiac Diagnostic Center

115 East 86th Street

New York, NY 10028

Tel: (212)-860-0796

https://newyorkcardiac.com/

Wall Street / Financial District Cardiology

New York Cardiac Diagnostic Center

65 Broadway, Suite 1806

New York, NY 10006

Tel: (212) 860-5404

https://newyorkcardiac.com/

Midtown Cardiology

200 West 57th Street

Suite 200

New York, NY 10019

(212) 582-8006

https://newyorkcardiac.com/

Source:

https://academic.oup.com/ehjcimaging/article/doi/10.1093/ehjci/jeaa178/5859292

https://www.acc.org/latest-in-cardiology/journal-scans/2020/07/13/12/20/incidence-of-stress-cardiomyopathy

Share article on social media or email:

HaloTherapy Center, LLC, Announces The Launch Of The Vitality Booth For The Health And Wellness Sector


HaloTherapy Center, LLC, the parent company of Salt Athletics and Salt Athletics Youth Training, is pleased to announce the launch of their new Vitality Booth product line. The Vitality Booth is a compact health and wellness device designed to deliver a patent-pending package of scientific wellness benefits in a single 15-minute session. Each Vitality Booth is made by hand with solid white cedar from Maine, and comes with four integrated Mito Red Lights and a choice of state of the art halo generators (dry salt inhalation). Available with each Vitality Booth are the optional features of FDA approved oxygen concentrators, negative ion generators and integrated blue UV light sanitizers for use in between sessions. An optional resistance band medical grade workout chair is also available for purchase and use with each Vitality Booth.

The Vitality Booth has a 4′ x 4′ footprint and stands 7 feet 3 inches tall. Vitality Booth’s offer individual user sessions in total privacy and are designed to be used in commercial and home settings, to include in fitness / wellness centers, doctors offices, nail salons, tanning salons, chiropractors, massage clinics, yoga studios, dermatologists offices, and in traditional salt inhalation wellness centers. Commercial customers can expect to generate over $300 a day in new revenue when making a single Vitality Booth available to consumers.

“We designed the Vitality Booth to deliver all the health and wellness benefits our traditional Salt Athletics rooms offer but in a compact turn-key unit,” said John Brier, Managing Partner of HaloTherapy Center, LLC. “When individuals experience a single 15-minute session in a Vitality Booth they see and feel the difference that our patent-pending scientific wellness platform delivers,” added Brier.

Each Vitality Booth session combines near and far red light therapy along with dry salt inhalation therapy in a patent-pending system that delivers the following benefits:


  • Anti-Aging natural face lift through collagen generation
  • Improved respiratory health (cold, cough, flu, sinusitis, COPD, allergies)
  • Improved skin health
  • Immune system boost through ATP creation at cellular level
  • Weight loss
  • Pain reduction / injury healing / wound healing
  • Athletic performance enhancement
  • Testosterone boost (men)
  • Hair growth (men)

“We recently added a Vitality Booth to World Gym Pensacola and it has quickly become the most in-demand amenity service in our new 13,000 square foot facility,” said Ed Weihenmayer, owner of World Gym Pensacola and World Gym Cantonment. “The Vitality Booth and the associated Salt Athletics scientific wellness platform has delivered innovative and in-demand wellness services to our members by fighting COVID through respiratory and immune system health benefits. While other gyms are struggling, the addition of Vitality Booth in my Pensacola facility has allowed me to generate significant revenue increases and new memberships during these uncertain times. Due to this demand, I am adding a second Vitality Booth to our World Gym Cantonment facility next month,” added Weihenmayer.

There are three models of Vitality Booth’s available for purchase:

1) Vitality Booth – Features red light therapy and halo therapy.

2) Vitality Booth Pro – Features red light therapy, halo therapy and oxygen therapy.

3) Vitality Booth Pro Max – Features red light therapy, halo therapy, oxygen therapy, negative ion therapy and integrated blue UV light sanitization.

Zero down financing is available to business owners looking to purchase Vitality Booth’s through Behalf, and financing is also available for residential customers through Afirm. Shipping is free in the continental U.S. and delivery times average 2-3 weeks. Assembly takes less than 2-hours.

You can learn more at http://www.VitalityBooth.com

Share article on social media or email:

David Murphey Photography announces a Hawaii landscape prints fundraiser to support Aloha Harvest


Yokohama Bay, Oahu. Scenic Hawaii landscape prints are now for sale on Indiegogo as a fundraiser for Aloha Harvest.

Families are going broke and going hungry. COVID-19 has intensified food insecurity in our state,” says David. “I’m hoping this project will highlight the adversity many Hawaii families face.”

Local photographer David Murphey has found a creative way to shed light on the many who have been affected by the COVID-19 crisis. With a 22% unemployment rate due to the economic shutdown, many families in Hawaii are going hungry, unable to buy necessities, most especially food. David has decided to lend a hand via his lens by selling fine-art prints of Hawaii landscape scenes on Indiegogo and donating all the proceeds to Aloha Harvest.

David is selling a limited edition of 100 large-format, fine-art prints of Hawaii landscape scenes on Indiegogo. Individual prints are priced at $75, with a set of two for $140. 100% of the net proceeds will

be donated to Aloha Harvest.

The fundraiser is now live on Indiegogo. https://igg.me/at/hawaiiprints

About David Murphey

David Murphey is a commercial photographer based in Honolulu, Hawaii. With more than 25 years of experience, he works with advertising agencies, graphic designers, public relation firms and their clients. For more information, visit https://davidmurphey.com or contact David at (808) 222-7011.

About Aloha Harvest

Aloha Harvest is the largest food rescue and redistribution organization in Hawaii. A 501c3 nonprofit, the organization picks up excess food from more than 250 donors and delivers it to at least 175 agencies feeding the hungry per year. All of their services are provided free of charge to both donors and recipients. So far in 2020, they’ve rescued and redistributed more than 1.2 million pounds of food that would have been wasted. For more information, visit https://alohaharvest.org or call (808) 537-6945.

Download high-res images here. https://bit.ly/2ZAbZKH

Source: David Murphey Photography

Share article on social media or email:

National Rebound in Plastic Surgery Interest Rings Especially True in Beverly Hills, Says Dr. J Plastic Surgery


Dr. J practices plastic surgery in Beverly Hills.

Waiting for the perfect time to do anything is never a great idea because perfect times don’t really exist.

A July 14 article on ABC News reports on statements from the American Society of Plastic Surgery that public interest in all types of plastic surgeries is on the rise nationally, according to the organization’s statistics. The organization noted that breast augmentation and liposuction were among the most commonly sought after procedures and that Botox and other “lunchtime” procedures remain very popular. Payam Jarrah-Nejad, M.D., F.I.C.S., F.A.C.S., known to his patients simply as Dr. J, says that the national statistics ring true for him in terms of the interest in obtaining procedures that he is seeing at his Beverly Hills office.

Dr. J says that, during the March and April lockdown, people were naturally leery of stepping into a doctor’s office, and, in any case, non-emergency procedures were out of the question during the period. However, as medical providers of all sorts have developed additional protocols to reduce the threat of the spread of any microbes at their offices and doctors have been permitted to start performing non-emergency procedures, people have started seriously again about what plastic surgeries they might like to obtain. Dr. J notes that he has always gone by the strictest protocols in terms of ensuring that plastic surgeries and other procedures are safe and sanitary. However, with the additional concerns related to COVID-19, he has undertaken measures to minimize direct contacts between patients and staff for the protection of all parties.

The double-board certified plastic surgeon notes that he is continuing to offers patients the option of virtual consultations but, now that visiting the office while wearing a mask and keeping a safe distance from others is now accepted practice, in-person consultations are available as well. Naturally, however, patients are asked to postpone any appointments if they don’t feel well or are suffering from a fever or respiratory symptoms.

Otherwise, says Dr. J. whether patients are contemplating breast or body contouring procedures such as tummy tucks, facelifts, or rhinoplasty, he encourages them to get in touch. Right now, he notes, the public health crisis looks to be with us for at least another several months. Waiting for the perfect time to do anything is never a great idea, adds the doctor, because perfect times don’t really exist. Of course, if patients have any questions or concerns relating to the safety of procedures in regards to preventing the spread of illnesses or any other matters, he and his team are always happy to answer, says Dr. J.

Readers who would like to learn more about an in-person or virtual consultation may call (310) 228-3151. Dr. J’s qualifications as a Beverly Hills plastic surgeon double-board certified by both the American Board of Plastic Surgery and the American Board of Surgery can be seen online.

Share article on social media or email:

CWCBExpo Launches CWCBEducation to Create First-of-its-Kind Entrepreneur Programs for Cannabis and Hemp Companies to Scale their Business


News Image

Our vision is to democratize business knowledge by creating pathways for entrepreneurs, regardless of background, education, race, nationality or gender, to learn, integrate, and participate in the wealth creation of this billion dollar industry.

CWCBEducation, a new business initiative from CWCBExpo (Cannabis World Congress & Business Expo), is the first-of-its-kind learning curriculums to help foreign and domestic cannabis, hemp, and CBD entrepreneurs prepare for US market entry or expand their established business.

“The industry is overdue for a comprehensive and credible education program that provides a multi-layered approach to learning, culminating with pitches to potential investors and customers,” said Leo Bridgewater, Head of Innovation, CWCBEducation and Advisory Committee Member, CWCBExpo. “Our vision is to democratize business knowledge by creating pathways for entrepreneurs, regardless of background, education, race, nationality or gender, to learn, integrate, and participate in the wealth creation of this billion dollar industry.”

The CWCBEducation programs will be based on the rich experience and content of Venture Hive, which has been designing, leading and executing global entrepreneur accelerator programs since 2013. Customized to the unique needs of the cannabis, hemp and CBD industries, the three (3) distinct programs will be offered prior to the CWCBExpo events in New York City (Oct. 1-3), Boston (Oct. 21-22), and Los Angeles (March 3-4, 2021).

The legal cannabis industry is still the fastest growing industry in the United States. In 2024, legal adult-use and medical cannabis sales are expected to exceed $30 billion, surpassing legacy industries including prescribed pain medication, OTC sleep aids, and other CPG categories.

“The CWCBExpo trade shows and conferences have been at the forefront of professionalizing the business side of the industry since 2014. CWCBEducation is the latest in expanding our product offerings and creating assets to credibly prepare companies for growth, scale and investment,” said Christine Ianuzzi, Managing Partner, CWCBExpo.

The CWCBEducation programs include:

US Market Entry for Entrepreneurs – 4 to 6 week program to help existing foreign entrepreneurs enter the US Market through strategic sales and partnerships, and making a debut through a CWCBExpo conference session launch. The program includes weekly cohort meetings, weekly individual mentoring, 10-20 hours of weekly content to complete assignments and includes show floor presence in the CWCBEducation Pavilion and conference registration fees at CWCBExpo.

Product Launch at CWCBExpo – 8 to 12 week program for NEW products to be launched at any CWCBExpo event. The program includes weekly cohort meetings, weekly individual mentoring, 15-20 hours of weekly content to complete assignments and is coupled with a show floor presence in the CWCBEducation Pavilion and conference registration fees at CWCBExpo.

Scale Your Business Accelerator – 8 to 12 week program for existing companies with $250K to $20M in annual revenue. The program includes weekly cohort meetings, weekly individual mentoring, 10-20 hours of weekly content to complete assignments and is coupled with show floor presence in the CWCBEducation Pavilion and conference registration fees at CWCBExpo.

For those companies that successfully complete any of the above programs, they will be invited to pitch their company during a showcase Demo Day (Live or Virtual) in front of a group of potential investors.

“This marks an exciting turning point for the industry with CWCBExpo leading the pack through this international education initiative tailored for domestic and foreign cannabis/hemp/CBD entrepreneurs and companies. Through these three distinct programs, we will be able to provide a solid business foundation from which to build and scale as CWCBEducation plays the role of guide and mentor,” added Dr. Susan Amat, Founder of Venture Hive and who currently serves as VP of Education of the Global Entrepreneurship Network (GEN).

Sergio Mankita, a seasoned marketing and business development executive, based out of Miami, FL will lead these initiatives as General Manager for CWCBEducation.

More information and registration can be found at: http://www.cwcbexpo.com/cwcbeducation.

About Cannabis World Congress & Business Expositions (CWCBExpo)

CWCBExpo are the premier business-to-business events for the legalized cannabis industry and held in the largest business, financial, and media markets—New York, Los Angeles and Boston. CWCBExpo also provides leading digital platforms to connect, engage and grow the cannabis industry including CWCBExpoWebinars and soon to be announced B2B engagement portal. For more information visit: http://www.cwcbexpo.com. Connect on Twitter, Facebook, Instagram, and LinkedIn: @cwcbexpo.

Share article on social media or email:

X.Labs Introduces PreCheck, a Digital Health Passport to Help Keep Schools, Workplaces, Events, and Sports Leagues Safe from COVID-19


PreCheck by X.Labs

This pandemic has changed everything about the way we live, work, and gather together. With PreCheck, there’s now a seamless way to bundle several essential components that can help us gather more safely in the future: testing, temperature checks, and identity verification

X.Labs, the leader in next-generation public safety threat detection and digital healthcare technologies, today introduced a novel product that incorporates virus test results,wellness and symptom survey questions, temperature readings, and other health data in an app designed to help keep schools, workplaces, concerts, stadiums, sporting arenas, amusement parks and large gatherings safer from COVID-19.

PreCheck by X.Labs is the first product to bundle the following components for safer, seamless health and safety screening and tracking in real-time, allowing for automated pre-approved entry into schools, large events and workplaces:


  • The Everlywell COVID-19 Test Home Collection Kit, an FDA-authorized product containing a diagnostic PCR test that provides results in as little as 24-48 hours from the time your sample is received by a certified lab
  • An FDA-approved bluetooth personal thermometer, a high-quality digital thermometer which shows whether your temperature is normal or elevated and records that information in the PreCheck app
  • Customizable in-app wellness and symptom survey which can be tailored to fit the requirements of the participating workplace or venue

PreCheck displays an individual’s COVID-19 test results, temperature history, and other health data with a workplace or venue’s customized Wellness Survey, which is created to further screen an individual against the business or venue’s health and safety requirements for entry into a building or space, and comply with tracking and reporting requirements.

How it works

Individuals who have PreCheck by X.Labs will use the included Everlywell COVID-19 Test Home Collection Kit at home and take their temperature using the included personal thermometer at a predetermined time before accessing a venue. PreCheck combines the COVID-19 test results, the individual’s temperature, and wellness surveys to produce a QR code. The venue’s requirements will determine if the QR code produces a passable result for safe entry, or a code that places the individual in a status of requiring further screening. Participating workplaces or venues will use READY, an X.Labs platform that customizes the building’s COVID-19 policy on-demand by allowing the administrator to set acceptable temperature ranges, create timelines for COVID-19 test results, and create a Wellness & Symptom Survey to help comply with visitor health, travel and contact tracing requirements. The venue can select whether they integrate only a single or multiple functionalities of PreCheck for their operating environment.

Once individuals arrive at an event with a QR code from their PreCheck app, they can bypass health and safety screening lines and gain entry by presenting their code in a contact-free manner. X.Labs has also partnered with some schools, workplaces, venues and major event organizers to automatically transmit individuals’ temperature and test results to user-selected destinations. The PreCheck app also makes it easy for consenting individuals to opt into X.Labs’ optional contact tracing program.

Once an individual has PreCheck by X.Labs, they can use their personal thermometer and app to seamlessly gain entry into a variety of participating events that require temperature checks and/or COVID-19 tests. Future integrations will include integration of COVID-19 vaccine records, once a vaccine is available. Additional COVID-19 test kits, if needed, can be ordered on Everlywell.com.

How to purchase

Interested schools, workplaces, airlines, venues, sporting arenas, teams, and other groups that oversee large events or mass transit of people can contact X.Labs at precheck.tech to purchase or to learn how they can incorporate PreCheck into their existing employee or end-user applications.

“We believe there has never been a more important moment to work together to solve one of the world’s most pressing problems. Through close cooperation and collaboration with Everlywell, we hope to harness the power of technology to help countries around the world slow the spread of COVID-19 and accelerate the return of everyday life,” said Todd Dunphy, COO of X.Labs.

“This pandemic has changed everything about the way we live, work, and gather together. With PreCheck, there’s now a seamless way to bundle several essential components that can help us gather more safely in the future: testing, temperature checks, and identity verification,” said Julia Cheek, CEO and Founder of Everlywell. “We look forward to working with X.Labs to help deliver the promise of safer workplaces and gatherings.”

About X.Labs

X.Labs is the leader in next-generation public safety threat detection and digital healthcare technologies and is a company dedicated to the development of cutting edge, high-speed checkpoint systems that detect emerging threats to civilians, buildings and law enforcement. The company’s patented thermography products are uniquely capable of detecting elevated temperature with their industry leading, mobile based fever detection product Feevr. The company’s revolutionary PreCheck app combines an individual’s temperature reading, viral testing and other health and safety data that helps keep buildings safer and businesses in compliance. Their patented millimeter wave detection technology X1, and XLe for Law Enforcement, detects concealed threats including weapons and explosive devices combined with advanced facial recognition and gunshot detection capabilities. X.Labs customers include Fortune 100 companies, entertainment venues, schools, international airports, airlines, stadiums, corporations, hospitals, large-scale events and national landmarks around the globe. Visit XLabs.tech for more information.

About Everlywell

Everlywell believes consumers deserve access to affordable lab tests and insightful, digitally-enabled results with actionable next steps. The company connects consumers to lab partners offering a suite of validated lab tests including Cholesterol, Heart Health, Fertility, STIs, Lyme Disease, Testosterone, Thyroid and more. Prices are straightforward starting at $49 and tests are generally covered by Flexible Spending and Health Savings Accounts. Physician-reviewed, actionable test results from CLIA-certified labs are provided within days of sample receipt. The company also provides testing for health plans, healthcare organizations, and employers, including some of the largest health plans in the nation.

The Austin-based company was founded in 2015 and is advised by a Scientific Advisory Board that includes some of the nation’s top scientists from Harvard, MIT, Google and NYU. Everlywell was selected as one of Fast Company’s Most Innovative Companies in 2019.

For more information please visit http://www.everlywell.com.

The Quinism Foundation Urges Caution in the Investigational and Off-Label Use of Tafenoquine Against COVID-19


The Quinism Foundation has called on clinical researchers and prescribers to exercise caution in the investigational and off-label use of tafenoquine against COVID-19, following an announcement of potential in-vitro efficacy of the drug against SARS-CoV-2 by 60 Degrees Pharmaceuticals (“60P”), the marketers of Arakoda®-branded tafenoquine, [1] as suggested by recent unpublished research. [2]

“As its ‘quine’ suffix indicates, tafenoquine is a quinoline antimalarial drug structurally related to hydroxychloroquine and chloroquine,” said Dr. Remington Nevin, MD, MPH, DrPH, a former U.S. Army public health physician and Johns-Hopkins trained psychiatric epidemiologist and drug safety expert, who now serves as Executive Director of The Quinism Foundation.

“All quinoline antimalarial drugs are amphiphilic and diprotic weak bases, which lead to their accumulation in acidic cellular endosomes, the property thought to at least partly underlie the observed antiviral activity of certain previously-tested drugs,” said Dr. Nevin. [3,4]

“Unfortunately, as experience with hydroxychloroquine and chloroquine has shown, the same common properties that likely underlie the observed effectiveness of these quinoline antimalarial drugs in-vitro against the virus may also underlie their common dangers,” said Dr. Nevin.

“In susceptible individuals, these drugs act as idiosyncratic neurotoxicants, potentially causing irreversible brain and brainstem dysfunction, even when used at relatively low doses,” said Dr. Nevin. “This drug-induced dysfunction causes a disease of the brain and brainstem called quinoline encephalopathy, or quinism, which can be marked by lasting psychiatric and neurological symptoms including tinnitus, dizziness, vertigo, paresthesias, visual disturbances, nightmares, insomnia, anxiety, agoraphobia, paranoia, psychosis, cognitive dysfunction, depression, personality change, and suicidal thoughts, among others,” said Dr. Nevin. [5]

“In recognition of tafenoquine’s neuropsychiatric liability, the FDA has required language in the approved U.S. drug label for Arakoda® warning of a risk of severe psychotic reactions, and that those taking the drug should be promptly evaluated by a medical professional if psychiatric symptoms occur during use, such as changes in mood, anxiety, insomnia, and nightmares if they are moderate and last more than three days or are severe.” [6]

Although the unpublished research paper accompanying 60P’s announcement suggests “proof of hope” for tafenoquine against COVID-19, in other words, an “expectation that pharmacologically relevant concentrations… can be achieved clinically and a likelihood that a relevant therapeutic index exists,” [2] Dr. Nevin notes that tafenoquine’s neurotoxicity may significantly narrow the drug’s therapeutic index for this proposed indication.

“In U.S. Army research conducted prior to 60P’s commercialization of tafenoquine, the drug was found to be the most neurotoxic quinoline among six tested, including mefloquine and chloroquine, and in cultured embryonic rat neurons, exhibited an IC50 of 12.1 µM,” said Dr. Nevin. [7] “This is less than threefold the concentration of 5.1 µM exhibiting EC90 against SARS-CoV-2 in VERO E6 cells in 60P’s unpublished research paper.” [2]

“While these results suggest promise against COVID-19, experience with chloroquine and hydroxychloroquine should temper institutional interest in similar investigational use of tafenoquine,” said Dr. Nevin. “Patients enrolled in whatever clinical trials may proceed must be informed of tafenoquine’s inherent neurotoxicity and neuropsychiatric liability. Likewise, prescribers should exercise caution against the ill-advised off-label use of either Arakoda®- or Krintafel®-branded tafenoquine, neither of which is FDA-approved for prevention or treatment of COVID-19.”

Dr. Nevin emphasized the importance of recognizing and properly reporting suspected adverse effects from prophylactic use of quinoline antimalarial drugs if these are used against COVID-19. “While it may be tempting to attribute anxiety, depression, paranoia, or other mental health symptoms to the psychological effects of the COVID-19 pandemic,” said Dr. Nevin, “these symptoms, if they occur during attempted use in prevention of disease, may be an early warning sign of idiosyncratic quinoline neurotoxicity. Likewise, more severe neuropsychiatric symptoms observed during or following attempted use of quinolines in treatment of COVID-19, including confusion or psychosis, may not necessarily be merely neurologic complications of the disease, but may represent potentially lasting adverse effects from the drug.”

Dr. Nevin noted that suspected adverse effects from tafenoquine and related quinoline drugs may be reported to the U.S. Food and Drug Administration’s MedWatch program, at

https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program.

About The Quinism Foundation

The Quinism Foundation, founded in January 2018, in White River Junction, Vermont, promotes and supports education and research on quinism, the family of medical disorders caused by exposure to quinoline drugs, including tafenoquine, chloroquine, hydroxychloroquine, and mefloquine.

Dr. Nevin is a board-certified occupational medicine and preventive medicine physician and former U.S. Army medical officer and epidemiologist. He is author of more than 30 scientific publications on malaria and the quinoline antimalarials, including “Neuropsychiatric Quinism: Chronic Encephalopathy Caused by Poisoning by Mefloquine and Related Quinoline Drugs,” published in the Springer Nature book, “Veteran Psychiatry in the US.”

(https://link.springer.com/chapter/10.1007/978-3-030-05384-0_20).

References

1. 60 Degrees Pharmaceuticals, LLC. 60 Degrees Pharmaceuticals Announces Positive Results of Cell Culture Testing of ARAKODA® (tafenoquine) for COVID-19. July 14, 2020. Available at: https://www.businesswire.com/news/home/20200714005355/en/60-Degrees-Pharmaceuticals-Announces-Positive-Results-Cell

2. Dow GS, Dc W, Fenner J, Yeo KR. Tafenoquine inhibits replication of SARS-Cov-2 at pharmacologically relevant concentrations in vitro. 2020. bioRxiv 2020.07.12.199059. Available at: https://doi.org/10.1101/2020.07.12.199059

3. Vincent MJ, Bergeron E, Benjannet S, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virology journal. 2005;2:69.

4. Yao X, Ye F, Zhang M, et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clinical infectious diseases. 2020. In press. doi:10.1093/cid/ciaa237

5. Nevin RL. Neuropsychiatric Quinism: Chronic Encephalopathy Caused by Poisoning by Mefloquine and Related Quinoline Drugs. In: Ritchie EC, Llorente MD, eds. Veteran Psychiatry in the US. Cham: Springer International Publishing; 2019:315-331.

6. 60 Degrees Pharmaceuticals. Arakoda (tafenoquine) Prescribing Information. August 2018. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210607lbl.pdf

7. Agboruche RL. 529.3 In-Vitro Toxicity Assessment of Antimalarial Drug Toxicity on Cultured Embryonic Rat Neurons, Macrophage (RAW 264.7), and Kidney Cells (VERO-CCl-81). FASEB Journal. 2009;23(1 Meeting Abstract Supplement):529.3.

Episcopal Relief & Development and Trinity Church Wall Street Announce Partnership in Response to COVID-19 Pandemic


Photo Courtesy of the Episcopal Anglican Church of Brazil

“We are deeply grateful for Trinity Church Wall Street’s generous support which will catalyze our efforts to respond to an increased number of vulnerable people around the world,” said Rob Radtke, President & CEO, Episcopal Relief & Development.

Episcopal Relief & Development and Trinity Church Wall Street are partnering on a response to the COVID-19 Pandemic. The partnership, supported by a $1,021,683 grant from Trinity Church Wall Street, will reach an estimated two million individuals with expanded relief efforts and strengthened resilience activities.

“COVID-19 has had a profound impact on the communities where we work, both as an immediate health threat as well as a longer-term threat to the livelihoods and health of the vulnerable populations we serve,” said Rob Radtke, President & CEO, Episcopal Relief & Development. “We are deeply grateful for Trinity Church Wall Street’s generous support which will catalyze our efforts to respond to an increased number of vulnerable people around the world.”

The partnership is addressing the effects of COVID-19 in 43 countries, with a priority focus on Bangladesh, Brazil, Burundi, Democratic Republic of Congo, Ecuador, Madagascar, Pakistan, Philippines, Puerto Rico, South Africa, South Sudan and Sri Lanka. The specific priority countries were chosen in order to best leverage both organizations’ existing partnerships for the greatest long-term, sustainable results.

“Trinity believes it is our responsibility to help our brothers and sisters not just here in New York City, but those around the world who are harmed by the pandemic, especially those in the most vulnerable regions,” said the Rev. Phillip A. Jackson, Priest-in-Charge and Vicar of Trinity Church Wall Street. “We are proud to partner with Episcopal Relief & Development and know that through their network, millions of people in need will be helped.”

Episcopal Relief & Development, with Trinity Church Wall Street’s support, is working with local Anglican and Episcopal dioceses and other partners, to create specific emergency programs tailored to the most urgent needs and the existing assets and networks in each community. Relief activities will include direct cash transfers to ensure vulnerable households can meet basic needs, the distribution of food, personal protective equipment and basic sanitation supplies such as soap, and/or educational campaigns to spread critical information related to COVID-19 prevention and control.

Additionally, the partnership is also supporting local communities in resilience-focused interventions to help them prepare for and manage the potential long-term economic and health effects of the pandemic. The organizations are working together to identify ways to increase income, while still maintaining physical distancing, and to contribute to immediate health and safety needs. These programs are focused on women’s empowerment and ensuring that children, particularly those under age three, continue to be safeguarded and supported.

“Episcopal Relief & Development and our network of faith-based partners have the experience and established relationships, structures and expertise to bring humanitarian support to communities affected by the COVID-19 pandemic,” said Abagail Nelson, Executive Vice President, Episcopal Relief & Development. “Our partners are already adapting and mobilizing to respond in ways to bring immediate relief while also creating long-term resilience.”

To learn more about Episcopal Relief & Development’s response to the novel coronavirus, visit episcopalrelief.org/covid-19-response. Donations to the COVID-19 Pandemic Response Fund will enable the organization to continue to provide emergency aid to vulnerable communities impacted by the pandemic, both in the United States and around the world.

About Episcopal Relief & Development:

For over 75 years, Episcopal Relief & Development has been working together with supporters and partners for lasting change around the world. Each year the organization facilitates healthier, more fulfilling lives for more than 3 million people struggling with hunger, poverty, disaster and disease. Inspired by Jesus’ words in Matthew 25, Episcopal Relief & Development leverages the expertise and resources of Anglican and other partners to deliver measurable and sustainable change in three signature program areas: Women, Children and Climate.

About Trinity Church Wall Street:

Now in its fourth century, Trinity Church Wall Street is a growing and inclusive Episcopal parish of more than 1,200 members that seeks to serve and heal the world by building neighborhoods that live Gospel truths, generations of faithful leaders, and sustainable communities. The parish is guided by its core values: faith, integrity, inclusiveness, compassion, social justice, and stewardship. Members come from the five boroughs of New York City and surrounding areas to form a racially, ethnically, and economically diverse congregation. More than 20 worship services are offered every week at its historic sanctuaries, Trinity Church and St. Paul’s Chapel, the cornerstones of the parish’s community life, worship, and mission, and online at trinitywallstreet.org. The parish welcomes approximately 2 million visitors per year.

Share article on social media or email:

LeadingBiotech’s Boston CEO&BD Conference Joins BioPharm America™ for a Must-Attend September Event


Boston CEO&BD

“Although we are unable to convene in person this year, we are thrilled to be welcoming all of our fantastic speakers digitally and to be offering our attendees an expanded reach across all of BioPharm America,” Wendy Nelson, CEO, LeadingBiotech.

LeadingBiotech, an exclusive event series bringing together senior-level biopharma leaders through off-the-record collaboration and dialogue, today announces its Boston CEO and Boston BD conferences are now one live virtual event to be held on September 22. Boston CEO&BD has joined with BioPharm America™ to offer the full content and partnering of the combined digitally-offered events to its attendees September 21–24.

Stay at the forefront of biotech innovation by tapping into the richest pool of finance, experience and talent. Boston CEO&BD provides an opportunity for attendees to leverage insight from real-life business development experiences, network with biopharma executives and share insights on the business challenges and opportunities impacting the industry.

Key topics at this year’s conference include the Role of Patient Advocacy Groups & Disease Foundations in our Ecosystem, Diversity & Inclusion: Cultivating the Next Generation of Biotech Execs, and Fireside Chats on Pricing and on Maximizing Value in an M&A.

As part of their registration, Boston CEO&BD attendees will have full access to BioPharm America, which includes a variety of diverse content from AI Applications for Drug Delivery and Development, Drug Delivery Partnerships, a Startup Pitch Competition, and the ability to set up pre-scheduled one-to-one virtual partnering meetings with participants from all these areas with EBD Group’s gold-standard partneringONE® platform.

There are four full days of partnering on a 24-hour schedule to accommodate time zones, as well as live and recorded panel discussions, fireside chats, and company presentations.

Speakers at Boston CEO&BD include:

Bruce Booth, Partner, Atlas Venture

Andy Plump, President, Research & Development, Takeda

Barbara Fox, CEO, Rheos Medicines

Adelene Perkins, CEO, Infinity Pharmaceuticals

Patrick Tricoli, CEO USA & Global Head of Business Development, Nanobiotix

Noubar Afeyan, Founder & CEO, Flagship Pioneering

Save $200 with the early bird rate if you register before July 24. Reserve your spot now.

About LeadingBiotech 

LeadingBiotech is an event series that brings biopharma CEOs and leaders together through intimate, off-the-record collaboration. We are working hard to create more valuable experiences to re-energize collaboration and infuse fresh ideas to better shape the future of biotech. For more information, please visit:https://leadingbiotech.com/.

Share article on social media or email: